To Compare The Effect Of Topical 0.5% Loteprednol Etabonate Versus 0.09% Bromfenac On Macular Thickness Following Nd:Yag Laser Capsulotomy In A Tertiary Care Hospital

Objective: To compare the effect of topical 0.5% Loteprednol etabonate versus 0.09% Bromfenac on Macular thickness after Nd:YAG laser capsulotomy and to compare the efficacy of Loteprednol and Bromfenac in preventing Cystoid macular edema. Methodology: It is a hospital based prospective randomised comparative study in which patients who developed PCO after uncomplicated cataract surgery were included in the study. Patients were randomly distributed in two groups 175 each, out of total 350 patients. Patients were prescribed topical 0.5% Loteprednol etabonate in Group 1and topical 0.09% Bromfenac in Group two after undergoing Nd: YAG laser capsulotomy. Visual acuity with snellen’s chart, IOP with non-contact tonometer, and macular thickness with OCT was assessed at 1 hour, 1 week, and 4 weeks after the procedure in both the groups. Results: The study recorded a significant improvement in visual acuity in both groups over time, with a notable percentage of patients achieving near-normal vision post-treatment. Also, there was no statistically significant difference observed in IOP and CMT among both the groups after the procedure. Conclusion: The research concluded equal efficacy of Loteprednol Etabonate and bromfenac on central macular thickness and other parameters post Nd YAG capsulotomy procedure.